Mangoselect®: Characterization, Pharmacokinetics and Bioavailability of Xanthone Metabolites
Launched by FYTEXIA · Nov 4, 2019
Trial Information
Current as of April 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Provision of signed and dated informed consent study
- • Stated willingness to comply with all the study procedures and availability for the duration of the study
- • Male and female
- • Normal BMI range (18.50-24.99)
- • In good general health as evidenced by medical history
- • Ability to take oral medication and be willing to adhere to lifestyle considerations
- Exclusion Criteria:
- • Current use of any medication or food supplement
- • Pregnancy or lactation
- • Known allergic reaction to mangosteen
- • Metabolic disorders or any kind of disease
- • Currant smoker
About Fytexia
Fytexia is a pioneering research and development company dedicated to the creation of innovative health solutions through the exploration of natural ingredients. With a strong focus on clinical trials and scientific validation, Fytexia harnesses cutting-edge methodologies to assess the efficacy and safety of its products, aimed at enhancing well-being across various health domains. The company is committed to advancing nutritional science and improving public health outcomes through rigorous research and collaboration with healthcare professionals and academic institutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Murcia, , Spain
Patients applied
Trial Officials
Pedro Alcaraz
Principal Investigator
UCAM
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials